1. Home
  2. EPAM vs ABVX Comparison

EPAM vs ABVX Comparison

Compare EPAM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPAM Systems Inc.

EPAM

EPAM Systems Inc.

N/A

Current Price

$150.61

Market Cap

7.9B

Sector

Technology

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$80.59

Market Cap

7.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EPAM
ABVX
Founded
1993
2013
Country
United States
France
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
7.7B
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
EPAM
ABVX
Price
$150.61
$80.59
Analyst Decision
Buy
Strong Buy
Analyst Count
19
12
Target Price
★ $172.88
$163.58
AVG Volume (30 Days)
★ 1.3M
792.9K
Earning Date
11-05-2026
09-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 6.00
N/A
Revenue
★ $1,450,448,000.00
N/A
Revenue This Year
$3.65
N/A
Revenue Next Year
$3.32
$1,695.54
P/E Ratio
$25.10
★ N/A
Revenue Growth
★ 25.02
N/A
52 Week Low
$73.06
$69.81
52 Week High
$222.53
$148.83

Technical Indicators

Market Signals
Indicator
EPAM
ABVX
Relative Strength Index (RSI) 54.73 39.18
Support Level $125.75 $74.79
Resistance Level $168.56 $94.67
Average True Range (ATR) 6.82 3.70
MACD -1.35 -0.17
Stochastic Oscillator 49.85 1.62

Price Performance

Historical Comparison
EPAM
ABVX

About EPAM EPAM Systems Inc.

EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: